Repeated switching between biosimilar ABP 654 and reference ustekinumab in patients with moderate-to-severe plaque psoriasis: a randomized, double-blinded clinical trial to support interchangeability

Clicks: 2
ID: 315295
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #262 of 313 articles by views in the british journal of dermatology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 313 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background ABP 654 is a biosimilar to ustekinumab reference product (RP). It is approved for the treatment of patients with moderate-to-severe plaque psoriasis and other autoimmune disorders. Objectives To demonstrate the interchangeability of ABP 654 and ustekinumab RP following multiple switches. Methods In this randomized, double-blinded study that evaluated pharmacokinetics (PK), efficacy, immunogenicity, and safety, patients with moderate-to-severe plaque psoriasis received a subcutaneous injection of ustekinumab RP 45 mg or 90 mg (baseline body weight ≤100 kg or >100 kg, respectively) on day 1 (week 0), week 4, and week 16 (Run-in Period). At week 28, patients with a 50% improvement in Psoriasis Area and Severity Index (PASI) or better response were randomized in a 1:1 ratio to the Continued-Use group or Switching group. Those in the Continued-Use group received ustekinumab RP at the same dose as in the Run-in Period at weeks 28, 40, and 52, while the Switching group received ABP 654 at week 28, ustekinumab RP at week 40, and ABP 654 at week 52. The primary endpoints were area under the curve over the dosing interval (AUCtau) and maximum concentration (Cmax) between weeks 52 and 64. Secondary endpoints included time to maximum concentration between weeks 52 and 64, trough concentration at steady state between weeks 28 and 52, PASI percent improvement from baseline at week 64, PASI 75 and PASI 100 responses at week 64, incidence of antidrug antibodies (ADAs), and incidence and severity of adverse events (AEs). Results Of the 494 enrolled patients, 453 successfully completed the Run-in period and were randomized to the Continued-Use (n = 225) or Switching (n = 228) groups. The point estimates and 90% confidence intervals (CIs) of the geometric mean ratios (GMRs) for AUCtau and Cmax between weeks 52 and 64 were 0.93 (0.89, 0.98) and 0.95 (0.90, 1.00), respectively. As both 90% CIs fell within the prespecified similarity margin of 0.8 to 1.25, PK similarity was demonstrated between the Switching and Continued-Use groups. In addition, efficacy, incidence of ADAs, and AEs were also similar between the groups. Conclusion These results support interchangeability of ABP 654 and ustekinumab RP.
Reference Key
openalex_W7162814111 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Andrew Blauvelt, Jerry Bagel, Andreas Pinter, Diamant Thaçi, Muhan Zhou, Jia Cao, Daniel T. Mytych, V Chow, Janet Franklin
Journal the british journal of dermatology
Year 2026
DOI
10.1093/bjd/ljag218
URL
https://doi.org/10.1093/bjd/ljag218
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.